NASDAQ
PULM
Last Price
US $1.62
KEY FIGURES
MKT CAP
$5.9M
EPS
TTM
$-1.24
PEG
TTM
-
P/E
TTM
N/M
P/S
TTM
-
YIELD
0.00%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Pulmatrix, Inc. carries no debt; cash flow comfortably covers obligations.
Financial stability - Healthy cash flow growth.
Pulmatrix, Inc.'s free cash flow has increased -51.12% from $-11.11M last year to $-5.43M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Pulmatrix, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Pulmatrix, Inc. has insufficient data to evaluate this check.
Financial risk - Net debt/EBITDA.
Pulmatrix, Inc. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Pulmatrix, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Pulmatrix, Inc.'s profit margin has increased (-100.00%) in the last year from -122.46% to 0.00%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Pulmatrix, Inc.'s short-term assets of $4.13M exceed its short-term liabilities of $329.00K
Decreasing performance - ROA.
Pulmatrix, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Pulmatrix, Inc.'s return on equity of -102.06%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Pulmatrix, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Pulmatrix, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Pulmatrix, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Pulmatrix, Inc. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Pulmatrix, Inc.'s yearly earnings has increased -46.00% since last year from $-9.56M to $-5.16M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
Pulmatrix, Inc.'s yearly revenue has decreased -100.00% since last year from $7.81M to $0.00, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -128.49% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Pulmatrix, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years
Increasing performance - Revenue consistency.
Pulmatrix, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Pulmatrix, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Pulmatrix, Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Pulmatrix, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Pulmatrix, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Pulmatrix, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Pulmatrix, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Pulmatrix, Inc. has a price-to-book ratio of 1.65x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Pulmatrix, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-102.06%
Return on equity
ROIC: -128.49%
Valuation History
-1.4X
Price to Earnings
EV/EBITDA: -0.66X
Cash flow
Profit margin
-
(FY vs FY)
EBITDA Y/Y
13.32%
(FY vs FY)
Cash flow Y/Y
18.63%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $1.62
—
Default assumptions
EBITDA Multiple
Fair Value
Market $1.62
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.